首页> 美国卫生研究院文献>Indian Journal of Surgical Oncology >The Results of the Combine Treatment of Patients with Liver Bilobar Metastases from Colorectal Cancer Using Radiofrequency Ablation
【2h】

The Results of the Combine Treatment of Patients with Liver Bilobar Metastases from Colorectal Cancer Using Radiofrequency Ablation

机译:射频消融联合治疗大肠癌肝双叶转移患者的疗效

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Colorectal cancer (CRC) is the third most common cancer worldwide. The mortality from CRC remains very high. The main cause of such a high mortality is a disseminate process with the appearance of distant metastases. In this regard, the treatment of metastatic lesions is recognized as an important trend in modern oncology. The program of study included 176 patients with colorectal cancer after primary tumor removal with the malignant progression—multiple (more than 4) bilobar liver metastases. The research was organized in Samara Regional Oncology Centre from 2001 to 2014. By the treatment method, patients were divided into two groups. Main group got the combined (chemotherapy + radiofrequency ablation (RFA)) treatment (n = 98). In control group, only chemotherapy was applied (n = 78). One-, two-, and three-year OS were 73.5, 25.1, and 7.2% in the main group and 39.6, 6.3, and 2.1% in the control group. The RFA application allowed us to reach the index of 4-year survival 1.8% in the main group, while we received only 2.1 of 3-year survival in the control group. The OS median reached 18 months in the main group and 11 months in the control group. So, the OS curves in two comparing groups were significantly different according to statistics (log-rank test 3.77, р = 0.000). The application of RFA in combination with chemotherapy in the treatment of bilobar metastasis colorectal cancer allows to improve the performance of disease-free survival and overall survival significantly, compared with the group of patients who received only chemotherapy.
机译:大肠癌(CRC)是全球第三大最常见的癌症。结直肠癌的死亡率仍然很高。如此高的死亡率的主要原因是扩散过程的出现以及远处转移的出现。在这方面,转移灶的治疗被认为是现代肿瘤学的重要趋势。该研究计划包括176例原发肿瘤切除后的大肠癌患者,其恶性进展为多发(超过4个)双叶肝转移。该研究于2001年至2014年在萨马拉地区肿瘤中心进行。根据治疗方法,将患者分为两组。主要组接受联合(化学疗法+射频消融(RFA))治疗(n = 98)。对照组仅应用化学疗法(n = 78)。主要组的一年,两年和三年OS为73.5%,25.1%和7.2%,对照组为39.6%,6.3%和2.1%。 RFA的应用使我们在主要组中达到了4年生存率1.8%的指标,而在对照组中我们仅获得2.1年3年生存率的指标。主要组的OS中位数为18个月,对照组为11个月。因此,根据统计数据,两个比较组中的OS曲线显着不同(对数秩检验3.77,=)0.000)。与仅接受化学疗法的患者相比,将RFA与化学疗法相结合治疗胆总管转移性结直肠癌可以显着改善无病生存期和总体生存期。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号